Holdings
Aisling Capital Management LP
As of Sep 30, 2026, Aisling Capital Management LP reported 13 positions worth US$295M. Largest: BridgeBio Pharma, Inc., Syndax Pharmaceuticals, Inc. and COMPASS Pathways Plc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| BridgeBio Pharma, Inc. | 3.09M | US$203M | −1.5M | Sep 30, 2026 |
| Syndax Pharmaceuticals, Inc. | 1.32M | US$24.8M | no change | Sep 30, 2026 |
| COMPASS Pathways Plc | 1.73M | US$21.6M | new | Sep 30, 2026 |
| Monte Rosa Therapeutics, Inc. | 1.56M | US$18.6M | no change | Sep 30, 2026 |
| Bicara Therapeutics Inc. | 549K | US$10.2M | −20,000 | Sep 30, 2026 |
| BridgeBio Oncology Therapeutics, Inc. | 1.02M | US$4.14M | no change | Sep 30, 2026 |
| Eupraxia Pharmaceuticals, Inc. | 325K | US$2.96M | no change | Sep 30, 2026 |
| Biomea Fusion, Inc. | 2.05M | US$2.74M | no change | Sep 30, 2026 |
| Aclaris Therapeutics, Inc. | 434K | US$2.29M | no change | Sep 30, 2026 |
| Scholar Rock Holding Corporation | 42,031 | US$2.03M | −35,000 | Sep 30, 2026 |